## Aetna Better Health® of Virginia REQUEST FORM Antimigraine Agents, Others Fax back to 1-855-799-2553

If the following information is not complete, correct, or legible, the PA process can be delayed. Please use one form per member.

MEMBER INFORMATION															
Last Name:	First Name:														
Medicaid ID Number:	Date of Birth:														
Condon Dagle Daniel	Woight in Vilograms:														
Gender: Male Female	Weight in Kilograms:														
PRESCRIBER INFORMATION															
Last Name:	First Name:														
NPI Number:															
Phone Number:	Fax Number:														
DRUG INFORMATION															
Drug Name/Form:															
Strength:															
	······································														
Dosing Frequency:															
Length of Therapy:															
Quantity per Day:															
Preventive treatm	nent of migraine														
Preferred Agents *step edit required	Non-Preferred Agents (PA required)														
Aimovig®, Ajovy® and Ajovy® autoinjector	Emgality® syringe (100 mg)														
Emgality® pen and syringe (120 mg), Nurtec® ODT	Qulipta™														
Acute treatmen	nt of migraine														
Preferred Agents (No PA with trial of 2 generic triptant	tans) Non-Preferred Agents (PA required)														
Nurtec® ODT, Ubrelvy™	Reyvow®, Trudhesa™														

(Form continued on next page.)

C16485-C Revised: 03/23/2023 | Effective: 07/01/2023 Page 1 of 4

Aetna Better Health® of Virginia Request Form: Antimigraine Agents, Others

Member's Last Name:											Member's First Name:												
DF	ORUG INFORMATION (Continued)																						
Ide	dentify why the preferred agents cannot be used.																						
DI	AGNO	OSIS A	AND IV	IEDIC	CALI	NFO	RM	ATIC	ON														
Αl	All drugs in this class are eligible to receive a SIX (6)-month approval. Complete the following questions.  For Preventive treatment of migraine, does the member meet the *step edit AND the following criteria?																						
Fo	r Prev	entiv	e treat	ment	of n	nigra	ine,	doe	s the	me	mb	er m	eet t	the *	step	edit	AND	) the	follo	wing	g crit	eria?	
1.	<ul> <li>Does the member have a diagnosis of migraine with or without aura based on International Classification of Headache Disorders (ICHD-III) diagnostic criteria? AND</li> <li>Yes</li> <li>No</li> </ul>															on							
2.	Is the	mem	ber≥1	8 yea	ırs of	f age	? <b>AN</b>	ND															
		'es	□ No	)																			
3.	Has	the m	ember	had 2	≥ 4 m	nigra	ine c	lays	per i	mont	th f	for at	leas	st 3 n	nont	hs? <b>/</b>	ND						
	Y	'es	☐ No	)																			
4.	*Has	the i	membe	r trie	d an	d fail	ed a	≥1।	mon	th tr	ial	of ar	ıy 2 d	of the	e foll	owin	g ora	al ger	neric	med	licatio	ons?	
	• E	Beta b	epressa lockers pileptic	s (e.g.	., pro	pran	olol,	, met	topr	olol,		-	, ateı	nolol	)								
	• /	Angiot	tensin c	onve	erting	genz	yme	inhil	bitor	s/an	gic	tens	in II ı	rece <sub>l</sub>	ptor	block	kers (	e.g.,	lisino	opril,	cano	desar	rtan)
		Yes [	No																				
Fo	r rene	wal,	comple	te th	e fol	llowi	ng q	uest	ion t	o re	cei	ve a	TWE	LVE	(12)-	mon	th ap	prov	/al.				
1.	Did t	he m	ember	demo	onstr	ate s	signii	fican	t de	creas	se i	n the	e nur	nber	, fred	quen	су, о	r inte	ensity	of h	neada	aches	s?
		'es	□ No	)																			
(Fo	orm co	ontinu	ıed on ı	next p	oage.	.)																	

C16485-C Revised: 03/23/2023 | Effective: 07/01/2023 Page 2 of 4

Member's Last Name:												Member's First Name:												
Fo	or Acute treatment of migraine, does the member meet the *step edit AND the following criteria?																							
1.	Does	the	men	nber	have	e a d	liagn	osis	of m	igrai	ne w	vith	or v	vitho	ut au	ıra?	AND							
	Y	Yes No																						
2.	. Is the member ≥ 18 years of age? <b>AND</b>																							
	Y	☐ Yes ☐ No																						
3.	*Has the member tried and failed (or has contraindications to) two preferred triptan medications?																							
	Y	Yes No																						
4.	Prior	to ir	nitiat	ion	of Tr	udhe	esa™	, a ca	ardic	ovaso	ular	ev	aluat	ion i	s rec	omn	nend	ed. F	las tl	nis be	een d	:ompl	etec	!?
	Y	es		No																				
Fo	rene	wal,	com	plet	e the	e fol	lowi	ng q	uest	ion t	o re	cei	ve a	TWE	LVE (	12)-	mon	th ap	prov	al.				
2.	Did t	he m	nemb	er d	emo	nstr	ate s	ignif	ican	t ded	reas	se i	n the	nun	nber,	frec	uen	cy, o	r inte	nsity	of h	eada	ches	?
	Y	es		No																				
(Fc	rm co	ntin	ued (	on ne	ext p	age.	)																	

C16485-C Revised: 03/23/2023 | Effective: 07/01/2023 Page 3 of 4

Member's Last Name:												Member's First Name:											
Foi	or Episodic Cluster Headache, does the member meet the the following criteria?															•							
1.	Does the member have a diagnosis of episodic cluster headache? <b>AND</b> Yes No																						
2.	Is the member ≥ 18 years of age? AND  Yes No																						
3.	<ul> <li>Has the member experienced at least 2 cluster periods lasting from 7 days to 365 days, separated by painfree periods lasting at least three months? AND</li> <li>Yes</li> <li>No</li> </ul>															ain-							
4.	<ul> <li>Medication will not be used in combination with another CGRP antagonist or inhibitor used for the preventive treatment of migraines? AND</li> <li>Yes</li> <li>No</li> </ul>																						
5.	Has the member tried and failed (or has contraindications to) at least one standard prophylactic (preventive) pharmacologic therapy for cluster headache?  Yes No																						
Foi	rene	wal,	comple	ete t	he fo	llowi	ng q	uest	ion to	o rec	eive	e a T	WE	LVE (	(12)-	mon	th ap	prov	al.				
1.		he m es	nember   No		nonsti	rate s	signi	fican	t dec	rease	e in	the	num	nber,	, frec	luend	cy, oı	r inte	ensity	of h	eada	iches	s?
Pre	Prescriber Signature (Required)																Da	ite					
-	By signature, the physician confirms the above information is accurate and verifiable by member records.  Please include ALL requested information; Incomplete forms will delay the PA process.																						

Submission of documentation does NOT guarantee coverage.

C16485-C

Revised: 03/23/2023 | Effective: 07/01/2023 Page 4 of 4